Iván A. González, Hsiang‐Chih Lu, Zahra Alipour, Sakil S. Kulkarni, Janis M. Stoll, Kim H.H. Liss, Louis P. Dehner, Mai He – 30 November 2020 – Centrilobular injury (CLI) is defined as the presence of perivenular mononuclear inflammation, hepatocyte dropout, and extravasated erythrocytes. In pediatric liver allografts, CLI has been associated with advanced fibrosis and chronic rejection (CR). We sought to better characterize the clinicopathologic features of CLI in the setting of T cell–mediated rejection (TCMR) and its association with complement component 4d (C4d) deposition.

Joy Varghese, Selvakumar Malleeswaran, Rajanikanth V. Patcha, Ellango Appusamy, Perumal Karnan, Dharmesh Kapoor, Kota Venugopal, Chandhan Kumar Kedarisetty, Balbir Singh, Prashantha S. Rao, Raghavendra Babu Yalakanti, Ravi Mohanka, Anurag Shrimal, Vinayak Nikam, Karan Kumar, Sunil D. Shenvi, Bhaskaran Pillai Venugopal, Nigel D. Heaton – 30 November 2020

Morteza Hafezi, Meiyin Lin, Adeline Chia, Alicia Chua, Zi Zong Ho, Royce Fam, Damien Tan, Joey Aw, Andrea Pavesi, Thinesh Lee Krishnamoorthy, Wan Cheng Chow, Wenjie Chen, Qi Zhang, Lu‐En Wai, Sarene Koh, Anthony T. Tan, Antonio Bertoletti – 29 November 2020

Philip R. Spradling, Yuna Zhong, Anne C. Moorman, Loralee B. Rupp, Mei Lu, Stuart C. Gordon, Eyasu H. Teshale, Mark A. Schmidt, Yihe G. Daida, Joseph A. Boscarino, for the Chronic Hepatitis Cohort Study (CHeCS) Investigators – 29 November 2020 – There are limited data examining the relationship between psychosocial factors and receipt of direct‐acting antiviral (DAA) treatment among patients with hepatitis C in large health care organizations in the United States. We therefore sought to determine whether such factors were associated with DAA initiation.

Tracey G. Simon, Andrew T. Chan, Curtis Huttenhower – 29 November 2020

May S. Freag, Bumseok Namgung, Maria E. Reyna Fernandez, Ermanno Gherardi, Shiladitya Sengupta, Hae Lin Jang – 29 November 2020 – Nonalcoholic steatohepatitis (NASH), an advanced stage of nonalcoholic fatty liver disease (NAFLD), is a rapidly growing and global health problem compounded by the current absence of specific treatments. A major limiting factor in the development of new NASH therapies is the absence of models that capture the unique cellular structure of the liver microenvironment and recapitulate the complexities of NAFLD progression to NASH.

Hye‐Mee Kwon, Young‐Jin Moon, Kyoung‐Sun Kim, Won‐Jung Shin, In‐Young Huh, In‐Gu Jun, Jun‐Gol Song, Gyu‐Sam Hwang – 28 November 2020

Diana Apetauerova, Peter Hildebrand, Stephanie Scala, Janet W. Zani, LeeAnne Lipert, Erin Clark, Tanya Fennell, Fredric D. Gordon – 26 November 2020 – Acquired hepatocerebral degeneration refers to a neurological syndrome consisting of various movement disorders and cognitive impairment in advanced liver cirrhosis or portosystemic shunt. Neurological signs and symptoms may be attributed to the accumulation of toxic substances in the brain. The most common neurological presentation of this is parkinsonism.

Gabriela Hernandez‐Meza, Johann Felden, Edgar E. Gonzalez‐Kozlova, Teresa Garcia‐Lezana, Judit Peix, Anna Portela, Amanda J. Craig, Sergi Sayols, Myron Schwartz, Bojan Losic, Vincenzo Mazzaferro, Manel Esteller, Josep M. Llovet, Augusto Villanueva – 25 November 2020

Ville Männistö, Dorota Kaminska, Pirjo Käkelä, Mikko Neuvonen, Mikko Niemi, Marcus Alvarez, Päivi Pajukanta, Stefano Romeo, Max Nieuwdorp, Albert.K. Groen, Jussi Pihlajamäki – 25 November 2020 – The protein phosphatase 1 regulatory subunit 3B (PPP1R3B) gene is a target of farnesoid X receptor (FXR), which is a major regulator of bile acid metabolism. Both PPP1R3B and FXR have been suggested to take part in glycogen metabolism, which may explain the association of PPP1R3B gene variants with altered hepatic computed tomography attenuation.